NovaVive Inc. - Canine

10/29/2024

NovaVive offers an immunotherapeutic alternative for the treatment of canine cancer that is USDA- and CFIA-approved for mammary adenocarcinoma - Immunocidin®.

By stimulating the immune system, Immunocidin has both a direct and indirect effect on tumor cells.

Beyond the anticancer effect, owners report that their treated pets have a good quality of life in terms of appetite, sleep, energy and overall comfort.

Ask your veterinarian about Immunocidin.

10/22/2024

We were sad to hear of the passing of Six, but we are pleased to have helped her live her best life for almost two years with Immunocidin.

This immunotherapy is regulator-approved in the USA and Canada for treating canine mammary cancer and is undergoing further research in other tumor types in both dogs and cats.

Learn more at http://novavive.ca/canine-research

10/15/2024

Immunocidin immunotherapy is approved by regulators in the USA and Canada for the treatment of canine mammary cancer.

NovaVive continues to explore other cancers for which Immunocidin may be effective. One of these is osteosarcoma (bone cancer).

Learn more about Immunocidin research at http://novavive.ca/canine-research.

10/09/2024

Immunocidin® immunotherapy has proven safe and effective as an intratumoral treatment for canine mammary cancer. Further research has demonstrated that it can also be safely administered by IV injection.

Immunocidin is approved by regulators in the USA and Canada. Research is ongoing with this product in various tumor types using different administration methods.

Visit NovaVive.ca/products for more information.

09/24/2024

Immunocidin has a two-way mode of action. It stimulates the immune system to fight cancer and the DNA of the active ingredient kills cancer cells.

This product is approved by regulators in the USA and Canada for the treatment of canine mammary cancer and is undergoing further research in other tumor types.

Visit NovaVive.ca/products to learn more.

09/24/2024

Please enjoy reading our latest quarterly business update newsletter (Volume 10, Issue 3) - https://tinyurl.com/twt9hfvx

09/11/2024

Immunocidin® immunotherapy works by stimulating direct and indirect anticancer activity in the dog.

The product is approved in the USA and Canada for treating canine mammary cancer and research is ongoing in other tumor types.

Visit NovaVive.ca/products to learn more

08/29/2024

NovaVive’s production process adheres to strict sterility standards, and all products undergo in-house testing to ensure purity, safety and potency.

Each batch is then reviewed by the USDA prior to its release into the market.

Visit NovaVive.ca for more information.

08/28/2024

Cancer cells don't live alone. That's why it's so hard to defeat them. 💔

They live in a complex environment surrounded by a variety of cells that end up becoming allies and enablers.

As the tumor grows, both the cancer cells and the nearby cells adapt their metabolism.
The cancer cells either work together or compete with the neighbors for nutrients to meet their energy and growth needs, all the while finding ways to avoid detection by the immune system and resist treatments.

08/27/2024

The most common type of bladder cancer in dogs is transitional cell carcinoma (TCC).

NovaVive is exploring the efficacy of Immunocidin immunotherapy in male dogs recently diagnosed with TCC in the bladder.

Immunocidin is approved by regulators in the USA and Canada for the treatment of canine mammary cancer and is undergoing further research in other tumor types.

Visit NovaVive.ca/products to learn more.

08/26/2024

It's International Dog Day!

NovaVive - and our canine family members - send best wishes for a happy day with your canine companion(s).

08/20/2024

We were sad to hear about the passing of Kipenzi the giraffe at Seneca Park Zoo (in Rochester, NY) and we send our condolences to the staff at the Zoo.

Kipenzi had been undergoing experimental treatment with Immunocidin, our anticancer immunotherapy, to treat a cancerous tumor in her jaw.

Immunocidin is approved by regulators in the USA and Canada for the treatment of canine mammary cancer and is undergoing further research in other tumor types.

Visit NovaVive.ca/products to learn more.

08/14/2024

Immunocidin is regulator-approved in the USA and Canada for treating canine mammary cancer and is undergoing further research in other tumor types, including appendicular osteosarcoma.

Visit NovaVive.ca/products for further information.

07/30/2024

Contact NovaVive for more information about our pilot research study in male dogs with TCC.

Max is a 12-year-old American Pitbull terrier diagnosed with Transitional Cell Carcinoma (TCC) in the bladder in Oct 2020, and started his immunotherapy protocol in the following month.

More than three years later, he shows no signs of bladder cancer. He has never had any negative side effects from the treatments at all.

This Immunocidin pilot study is enrolling dogs with TCC or urothelial carcinoma. The hope is that patients can enjoy very LONG remission with very little side-effects, and return to being happy and healthy as all dogs deserve. ❤️

07/24/2024

NovaVive is always seeking opportunities to expand the reach of our products. We conduct research studies to identify additional indications that may respond to our therapies. One of these studies involves Immunocidin in dogs with appendicular osteosarcoma. This is an ongoing study, but results to date are promising.

Immunocidin has regulatory approval in the USA and Canada for treating mammary cancer in dogs.

Learn more at NovaVive.ca/products or NovaVive.ca/canine-research

07/19/2024

07/09/2024

Immunocidin immunotherapy works by stimulating the body's immune system to fight cancer. The DNA of the active ingredient has been shown to kill tumor cells.

This product is approved by regulators in the USA and Canada for the treatment of canine mammary cancer and is undergoing further research in other tumor types.

Visit NovaVive.ca/products to learn more.

06/18/2024

Please enjoy reading our latest quarterly business update newsletter (Volume 10, Issue 2) - https://tinyurl.com/4kz8vcxz

06/06/2024

Pickles is one of several dogs with osteosarcoma to receive Immunocidin immunotherapy as an experimental treatment. We’re pleased to have helped Pickles continue to live his best life for more than a year despite his cancer diagnosis.

Immunocidin is approved by regulators in the USA and Canada for the treatment of canine mammary cancer and is undergoing further research in other tumor types, including osteosarcoma.

Visit NovaVive.ca/products to learn more.

05/29/2024

We hear from hundreds of pet owners each year, many hoping to find out more information about treatment options for their pet, searching for assistance with funding the needed treatment, and requesting information on specialties such as radiation and surgical oncology. While VCS does not fund treatm...

05/23/2024

We were sad to hear of the passing of Cougar, but we are pleased to have helped him live his best life for more than 3 years with Immunocidin.

This immunotherapy is regulator-approved in the USA and Canada for treating canine mammary cancer and is undergoing further research in other tumor types in both dogs and cats.

05/21/2024

Immunocidin is regulator-approved in the USA and Canada for treating canine mammary cancer and is undergoing further research in other tumor types, including appendicular osteosarcoma.

Visit NovaVive.ca/products for further information.